Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancer ...

In the wake of Anthropic’s announcement of its latest artificial intelligence model, Mythos, on April 7, the company has stood by an unusual decision: refusing to release it to the public. Not since ...

Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May ...

Selective estrogen receptor modulators (SERMs) are nonsteroidal compounds that exert context-dependent agonist or antagonist effects on estrogen receptors through ligand-induced conformational changes ...

The 10-year disease-free survival rates were 80.1% with an AI and 76.5% with a SERM. Treatment with an aromatase inhibitor (AI) improves outcomes at 10 years compared to a selective estrogen receptor ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...

Introduction: Cardiovascular (CV) diseases are a major cause of morbidity and mortality in breast cancer survivors. Side effects of antineoplastic agents used in treating breast cancer have been known ...